指南与共识胸部肿瘤

肺类癌TNM分期指南预后意义的评估

Evaluation of the Prognostic Significance of TNM Staging Guidelines in Lung Carcinoid Tumors.
指南 / 共识 · J Thorac Oncol · 2018-11-08

该研究基于美国SEER登记库2000至2013年诊断的4645例典型与非典型支气管肺类癌患者,采用竞争风险分析比较各期10年疾病特异性生存(DSS)。第八版TNM分期各合并期别可提供预后信息,但相邻亚组及合并期别间存在持续重叠,尤其在中问期别,限制了其应用价值。

要点

  • 典型与非典型肺类癌中,DSS随TNM状态和分期加重而下降,但相邻亚组间存在重叠。
  • 合并期别(I对II、II对III、III对IV)的DSS分离度优于亚组,但组间仍有重叠。
  • 典型类癌中,与I期相比,II、III、IV期DSS下降的HR分别为3.8、4.3、9.0。

核心结论

  • 第八版TNM分期的合并期别可为典型与非典型类癌的预后提供有用信息。
  • 合并期别及亚组中持续存在的重叠限制了TNM分期的应用价值,尤其在中间期别。
  • 这些局限提示未来需进一步研究和完善。

研究设计与样本

  • 基于美国国家癌症研究所SEER登记库的回顾性人群研究。
  • 纳入2000至2013年诊断的典型与非典型支气管肺类癌患者,共4645例。
  • 采用竞争风险分析比较各期10年疾病特异性生存(DSS)。

主要发现

  • 整体4645例患者中,典型与非典型类癌均显示DSS随TNM状态和分期加重而下降,相邻亚组间存在重叠。
  • 合并期别(I对II、II对III、III对IV)的DSS分离度更大,但组间仍有持续重叠。
  • 典型类癌中,与I期相比,II期DSS下降的HR为3.8(95%CI:2.6-5.6)。
  • 典型类癌中,与I期相比,III期DSS下降的HR为4.3(95%CI:3.0-6.1)。
  • 典型类癌中,与I期相比,IV期DSS下降的HR为9.0(95%CI:6.1-13.1)。

局限性

  • 合并期别及分期系统亚组中持续存在的重叠限制了TNM分期的应用价值,尤其在中间期别。
  • 这些局限提示未来需进一步研究和完善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The TNM classification for lung cancer, originally designed for NSCLC, is applied to staging of bronchopulmonary carcinoid tumors. The validity of the eighth edition of the staging system for carcinoid tumors has not been assessed. In this study, we evaluated its prognostic accuracy by using data from a large national population-based cancer registry. METHODS: Patients with typical and atypical bronchopulmonary carcinoids diagnosed between 2000 and 2013 were identified from the National Cancer Institute's Surveillance, Epidemiology and End Results registry. We used competing risks analysis to compare 10-year disease-specific survival (DSS) across stages. RESULTS: Overall, 4645 patients with bronchopulmonary carcinoid tumors were identified. Worsening DSS with increasing TNM status and stage was demonstrated across both typical and atypical carcinoids, with overlaps between adjacent subcategories. The combined stages (I versus II, II versus III, and III versus IV) showed greater separation in DSS despite persistent overlaps between groups. For typical carcinoids, we found decreased DSS for stages II, III, and IV, with hazard ratios of 3.8 (95% confidence interval [CI]: 2.6-5.6), 4.3 (95% CI: 3.0-6.1), and 9.0 (95% CI: 6.1-13.1), respectively, compared with stage I. CONCLUSION: The combined stage categories of the eighth edition of the TNM staging system provide useful information on outcomes for typical and atypical carcinoids. However, persistent overlaps in combined stage and subcategories of the staging system limit the usefulness of the TNM staging system, particularly in intermediate stages. These limitations suggest the need for future further study and refinement.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yoon JY, Sigel K, Martin J, et al. Evaluation of the Prognostic Significance of TNM Staging Guidelines in Lung Carcinoid Tumors. J Thorac Oncol. 2018. PMID: 30414942. doi:10.1016/j.jtho.2018.10.166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。